The Potential of Using Induced Pluripotent Stem Cells in Skin Diseases

Cell and Molecular Biology and Imaging of Stem Cells

Volumn 9781118284100, Issue , 2014, Pages 223-245

  Ohta, Shigeki ^a   Veraitch, Ophelia ^a,b   Okano, Hideyuki ^a   Ohyama, Manabu ^a   Kawakami, Yutaka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cancer stem cells; Induced pluripotent stem cells (iPSCs); Keratinocytes; Melanocytes

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; DERMATOLOGY; DISEASES; GENE THERAPY; ONCOLOGY; REGENERATIVE MEDICINE; SKIN;

CANCER STEM CELLS; CELL POPULATIONS; INDUCED PLURIPOTENT STEM CELL; INDUCED PLURIPOTENT STEM CELLS; KERATINOCYTES; MELANOCYTE; REGENERATIVE MEDICINE; SKIN DISEASE; STEM CELL BIOLOGY; STEM-CELL;

STEM CELLS;

EID: 84926405414     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118285602.ch10     Document Type: Chapter

References (139)

1. Abu Tahir M, Pramod K, Ansari SH, Ali J. 2010. Current remedies for vitiligo. Autoimmun Rev 9: 516-20.
2. Aasen T, Raya A, Barrero MJ, et al. 2008. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26: 1276-1284.
3. Aoi T, Yae K, Nakagawa M, et al. 2008. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321: 699-702.
4. Baker M. 2011. Stem-cell pioneer bows out.. Nature 479: 459.
5. Banito A, Gil J. 2010. Induced pluripotent stem cells and senescence: learning the biology to improve the technology. EMBO Rep 11: 353-9.
6. Ben-David U, Benvenisty N. 2011. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11: 268-77.
7. Biddle A, Liang X, Gammon L, et al. 2011. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 71: 5317-26.
8. Bilousova G, Chen J, Roop DR. 2011. Differentiation of mouse induced pluripotent stem cells into a multipotent keratinocyte lineage. J Invest Dermatol 131: 857-64.
9. Blanpain C. 2013. Tracing the cellular origin of cancer. Nat Cell Biol 15: 126-34.
10. Bluestone JA, Small EJ. 2012. The future of cancer treatment: will it include immunotherapy?. Cancer Cell 22: 7-8.
11. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. 2012. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11: 873-86.
12. Brabletz T. 2012. EMT and MET in metastasis: where are the cancer stem cells?. Cancer Cell 22: 699-701.
13. Brownell I, Guevara E, Bai CB, Loomis CA, Joyner AL. 2011. Nerve-derived sonic hedgehog defines a niche for hair follicle stem cells capable of becoming epidermal stem cells. Cell Stem Cell 8: 552-65.
14. Carpenter MK, Frey-Vasconcells J, Rao MS. 2009. Developing safe therapies from human pluripotent stem cells. Nat Biotechnol 27: 606-13.
15. Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, Jaenisch R. 2009. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci USA 106: 157-62.
16. Chang CW, Lai YS, Pawlik KM, et al. 2009. Polycistronic lentiviral vector for. hit and run. reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 27: 1042-9.
17. Clayton E, Doupe DP, Klein AM, Winton DJ, Simons BD, Jones PH. 2007. A single type of progenitor cell maintains normal epidermis. Nature 446: 185-9.
18. Clevers H. 2011. The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-19.
19. Colmont CS, Harding KG, Piguet V, Patel GK. 2012. Human skin cancer stem cells: a tale of mice and men. Exp Dermatol 21: 576-80.
20. Cotsarelis G, Sun TT, Lavker RM. 1990. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 61: 1329-37.
21. Cunningham JJ, Ulbright TM, Pera MF, Looijenga LH. 2012. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol 30: 849-57.
22. Dalerba P, Cho RW, Clarke MF. 2007. Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284.
23. Daley GQ. 2012. The promise and perils of stem cell therapeutics. Cell Stem Cell 10: 740-9.
24. Dessinioti C, Stratigos AJ, Rigopoulos D, Katsambas AD. 2009. A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes. Exp Dermatol 18: 741-749.
25. Ding Q, Lee YK, Schaefer EA, et al. 2013. A TALEN Genome-Editing System for Generating Human Stem Cell-Based Disease Models. Cell Stem Cell 12: 238-51.
26. Doupe DP, Jones PH. 2012. Interfollicular epidermal homeostasis: dicing with differentiation. Exp Dermatol 21: 249-253.
27. Ehama R, Ishimatsu-Tsuji Y, Iriyama S, et al. 2007. Hair follicle regeneration using grafted rodent and human cells. J Invest Dermatol 127: 2106-15.
28. Ernfors P. 2010. Cellular origin and developmental mechanisms during the formation of skin melanocytes. Exp Cell Res 316: 1397-407.
29. Fang D, Leishear K, Nguyen TK, et al. 2006. Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells 24: 1668-77.
30. Festa E, Fretz J, Berry R, et al. 2011. Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling. Cell 146: 761-71.
31. Fisher R, Pusztai L, Swanton C. 2013. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108: 479-85.
32. Friedmann-Morvinski D, Bushong EA, Ke E, et al. 2012. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338: 1080-1084.
33. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD. 2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31(9): 822-6.
34. Fujiwara H, Ferreira M, Donati G, et al. 2011. The basement membrane of hair follicle stem cells is a muscle cell niche. Cell 144: 577-89.
35. Galach M, Utikal J. 2011. From skin to the treatment of diseases - the possibilities of iPS cell research in dermatology. Exp Dermatol 20: 523-8.
36. Ghazizadeh S, Taichman LB. 2001. Multiple classes of stem cells in cutaneous epithelium: a lineage analysis of adult mouse skin. EMBO J 20: 1215-22.
37. Goldring CE, Duffy PA, Benvenisty N, et al. 2011. Assessing the safety of stem cell therapeutics. Cell Stem Cell 8: 618-28.
38. Grichnik JM. 2008. Melanoma, nevogenesis, and stem cell biology. J Invest Dermatol 128: 2365-80.
39. Guenou H, Nissan X, Larcher F, et al. 2009. Human embryonic stem-cell derivatives for full reconstruction of the pluristratified epidermis: a preclinical study. Lancet 374: 1745-53.
40. Guha P, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS. 2013. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12(4): 407-412.
41. Haase I, Knaup R, Wartenberg M, Sauer H, Hescheler J, Mahrle G. 2007. In vitro differentiation of murine embryonic stem cells into keratinocyte-like cells. Eur J Cell Biol 86: 801-5.
42. Hanna J, Markoulaki S, Schorderet P, et al. 2008. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133: 250-64.
43. Hatina J. 2012. The dynamics of cancer stem cells. Neoplasma 59: 700-7.
44. Hermann PC, Huber SL, Herrler T, et al. 2007. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-23.
45. Higgins CA, Itoh M, Inoue K, Richardson GD, Jahoda CA, Christiano AM. 2012. Reprogramming of human hair follicle dermal papilla cells into induced pluripotent stem cells. J Invest Dermatol 132: 1725-7.
46. Ho R, Chronis C, Plath K 2011. Mechanistic insights into reprogramming to induced pluripotency. J Cell Physiol 226(4): 868-78.
47. Hockemeyer D, Soldner F, Beard C, et al. 2009. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27: 851-7.
48. Horsley V, O'Carroll D, Tooze R, et al. 2006. Blimp1 defines a progenitor population that governs cellular input to the sebaceous gland. Cell 126: 597-609.
49. Hussein SM, Nagy AA 2012. Progress made in the reprogramming field: new factors, new strategies and a new outlook. Curr Opin Genet Dev 22(5): 435-43.
50. Itoh M, Kiuru M, Cairo MS, Christiano AM. 2011. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc Natl Acad Sci USA 108: 8797-802.
51. Iuchi S, Dabelsteen S, Easley K, Rheinwald JG, Green H 2006. Immortalized keratinocyte lines derived from human embryonic stem cells. Proc Natl Acad Sci USA 103: 1792-7.
52. Ito M, Yang Z, Andl T, Cui C, Kim N, Millar SE, Cotsarelis G. 2007. Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature 447(7142): 316-20.
53. Ji L, Allen-Hoffmann BL, de Pablo JJ, Palecek SP. 2006. Generation and differentiation of human embryonic stem cell-derived keratinocyte precursors. Tissue Eng 12: 665-79.
54. Kidwai FK, Liu H, Toh WS, et al. 2012. Differentiation of human embryonic stem cells into clinically amenable keratinocytes in an autogenic environment. J Invest Dermatol 133: 618-628.
55. Kim JB, Sebastiano V, Wu G, et al. 2009. Oct4-induced pluripotency in adult neural stem cells. Cell 136: 411-19.
56. Kim K, Doi A, Wen B, et al. 2010. Epigenetic memory in induced pluripotent stem cells. Nature 467: 285-90.
57. Knoepfler PS. 2009. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 27: 1050-6.
58. Kumano K, Arai S, Hosoi M, et al. 2012. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 119: 6234-642.
59. Lee G, Chambers SM, Tomishima MJ, Studer L. 2010. Derivation of neural crest cells from human pluripotent stem cells. Nat Protoc 5: 688-701.
60. Lemaitre G, Nissan X, Baldeschi C, Peschanski M. 2011. Concise review: Epidermal grafting:the case for pluripotent stem cells. Stem Cells 29: 895-9.
61. Li L, Fukunaga-Kalabis M, Yu H, et al. 2010. Human dermal stem cells differentiate into functional epidermal melanocytes. J Cell Sci 123: 853-60.
62. Li W, Wei W, Zhu S, et al. 2009. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4: 16-19.
63. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. 2009. Increasing burden of melanoma in the United States. J Invest Dermatol 129: 1666-74.
64. Liu C, Sage JC, Miller MR, et al. 2011. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146: 209-21.
65. Liu H, Zhu F, Yong J, et al. 2008. Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 3: 587-90.
66. Lu CP, Polak L, Rocha AS, et al. 2012. Identification of stem cell populations in sweat glands and ducts reveals roles in homeostasis and wound repair. Cell 150: 136-50.
67. Lyle S, Christofidou-Solomidou M, Liu Y, Elder DE, Albelda S, Cotsarelis G. 1998. The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci 111(21): 3179-88.
68. Mackenzie IC, Bickenbach JR. 1985. Label-retaining keratinocytes and Langerhans cells in mouse epithelia. Cell Tissue Res 242: 551-6.
69. Magee JA, Piskounova E, Morrison SJ. 2012. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-96.
70. Mali P, Yang L, Esvelt KM, et al. 2013. RNA-guided human genome engineering via Cas9. Science 339: 823-6.
71. Mani SA, Guo W, Liao MJ, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-15.
72. Marusyk A, Almendro V, Polyak K. 2012. Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer 12: 323-34.
73. Menendez L, Kulik MJ, Page AT, et al. 2013. Directed differentiation of human pluripotent cells to neural crest stem cells. Nat Protoc 8: 203-12.
74. Miyoshi N, Ishii H, Nagai K, et al. 2010. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA 107: 40-5.
75. Morris RJ, Fischer SM, Slaga TJ. 1985. Evidence that the centrally and peripherally located cells in the murine epidermal proliferative unit are two distinct cell populations. J Invest Dermatol 84: 277-81.
76. Morris RJ, Liu Y, Marles L, et al. 2004. Capturing and profiling adult hair follicle stem cells. Nat Biotechnol 22: 411-17.
77. Nakamura M, Okano H. 2013. Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells. Cell Res 23(1): 70-80.
78. Nguyen LV, Vanner R, Dirks P, Eaves CJ. 2012. Cancer stem cells: an evolving concept. Nat Rev Cancer 12: 133-43.
79. Nishimura EK. 2011. Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation. Pigment Cell Melanoma Res 24: 401-10.
80. Nishimura EK, Jordan SA, Oshima H, et al. 2002. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416: 854-60.
81. Nishimura EK, Granter SR, Fisher DE. 2005. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 307: 720-4.
82. Nissan X, Larribere L, Saidani M, et al. 2011. Functional melanocytes derived from human pluripotent stem cells engraft into pluristratified epidermis. Proc Natl Acad Sci USA 108: 14861-6.
83. Ohta S, Imaizumi Y, Okada Y, et al. 2011. Generation of human melanocytes from induced pluripotent stem cells. PLOS ONE 6: e16182.
84. Ohyama M, Terunuma A, Tock CL, et al. 2006. Characterization and isolation of stem cellenriched human hair follicle bulge cells. J Clin Invest 116: 249-60.
85. Ohyama M, Zheng Y, Paus R, Stenn KS. 2010. The mesenchymal component of hair follicle neogenesis: background, methods and molecular characterization. Exp Dermatol 19: 89-99.
86. Ohyama M, Kobayashi T, Sasaki T, Shimizu A, Amagai M. 2012. Restoration of the intrinsic properties of human dermal papilla in vitro. J Cell Sci 125: 4114-25
87. Okita K, Matsumura Y, Sato Y, et al. 2011. A more efficient method to generate integration-free human iPS cells. Nat Methods 8(5): 409-12.
88. Oliver RF. 1966. Whisker growth after removal of the dermal papilla and lengths of follicle in the hooded rat. J Embryol Exp Morphol 15: 331-47.
89. Poulson ND, Lechler T. 2010. Robust control of mitotic spindle orientation in the developing epidermis. J Cell Biol 191: 915-22.
90. Ott PA, Hodi FS, Robert C. 2013. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19(19): 5300-9.
91. Poulson ND, Lechler T. 2010. Robust control of mitotic spindle orientation in the developing epidermis. J Cell Biol 191: 915-22.
92. Puri MC, Nagy A. 2012. Concise review: Embryonic stem cells versus induced pluripotent stem cells: the game is on. Stem Cells 30: 10-14.
93. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18(5): 510-23.
94. Rabbani P, Takeo M, Chou W, et al. 2011. Coordinated activation of Wnt in epithelial and melanocyte stem cells initiates pigmented hair regeneration. Cell 145: 941-55.
95. Ramos-Mejia V, Fraga MF, Menendez P. 2012. iPSCs from cancer cells: challenges and opportunities. Trends Mol Med 18(5): 245-7.
96. Rao MS, Malik N. 2012. Assessing iPSC reprogramming methods for their suitability in translational medicine. J Cell Biochem 113: 3061-8.
97. Restifo NP, Dudley ME, Rosenberg SA. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-81.
98. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. 2010. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-94.
99. Santamaria P, Rodriguez-Piza I, Clemente-Casares X, et al. (2010) Turning human epidermis into pancreatic endoderm. Rev Diabet Stud 7(2):158-67.
100. Scaffidi P, Misteli T. 2011. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 13(9): 1051-61.
101. Schwartz SD, Hubschman JP, Heilwell G, et al. 2012. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379: 713-20.
102. Schwitalla S, Fingerle AA, Cammareri P, et al. 2013. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152: 25-38.
103. Semi K, Matsuda Y, Ohnishi K, Yamada Y. 2013. Cellular reprogramming and cancer development. Int J Cancer 132: 1240-8.
104. Soldner F, Hockemeyer D, Beard C, et al. 2009. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136: 964-77.
105. Somers A, Jean JC, Sommer CA, et al. 2010. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 28: 1728-40.
106. Stadtfeld M, Brennand K, Hochedlinger K. 2008. Reprogramming of pancreatic beta cells into induced pluripotent stem cells. Curr Biol 18: 890-4.
107. Stenn KS. 2001. Insights from the asebia mouse: a molecular sebaceous gland defect leading to cicatricial alopecia. J Cutan Pathol 28: 445-7.
108. Sugihara E, Saya H. 2013. Complexity of cancer stem cells. Int J Cancer 132: 1249-59.
109. Taapken SM, Nisler BS, Newton MA, et al. 2011. Karyotypic abnormalities in human induced pluripotent stem cell and embryonic stem cells. Nat Biotechnol 29: 312-313.
110. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-76.
111. Takahashi K, Tanabe K, Ohnuki M, N. et al. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-72.
112. Tang C, Lee AS, Volkmer JP, et al. 2011. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 29: 829-34.
113. Tanimura S, Tadokoro Y, Inomata K, et al. 2011. Hair follicle stem cells provide a functional niche for melanocyte stem cells. Cell Stem Cell 8: 177-87.
114. Thieu K, Ruiz ME, Owens DM. 2012. Cells of origin and tumor-initiating cells for nonmelanoma skin cancers. Cancer Lett 338(1): 82-8.
115. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282: 1145-7.
116. Tolar J, Xia L, Riddle MJ, et al. 2011. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 131: 848-56.
117. Tolar J, Xia L, Lees CJ, et al. 2013. Keratinocytes from induced pluripotent stem cells in junctional epidermolysis bullosa. J Invest Dermatol 133: 562-5.
118. Tomita Y, Suzuki T. 2004. Genetics of pigmentary disorders. Am J Med Genet C Semin Med Genet 131C: 75-81.
119. Trempus CS, Morris RJ, Bortner CD, et al. 2003. Enrichment for living murine keratinocytes from the hair follicle bulge with the cell surface marker CD34. J Invest Dermatol 120: 501-11.
120. Tsai SY, Clavel C, Kim S, et al. 2010. Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem cells. Stem Cells 28: 221-8.
121. Tsai SY, Bouwman BA, Ang YS, et al. 2011. Single transcription factor reprogramming of hair follicle dermal papilla cells to induced pluripotent stem cells. Stem Cells 29: 964-971.
122. Tumbar T, Guasch G, Greco V, et al. 2004. Defining the epithelial stem cell niche in skin. Science 303: 359-63.
123. Uitto J. 2011. Regenerative medicine for skin diseases: iPS cells to the rescue. J Invest Dermatol 131: 812-14.
124. Utikal J, Maherali N, Kulalert W, Hochedlinger K. 2009. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 122: 3502-10.
125. Veraitch O, Kobayashi T, Imaizumi Y, et al. 2013. Human induced pluripotent stem cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vitro. J Invest Dermatol 133(6): 1479-88.
126. Vierbuchen T, Wernig M. 2011. Direct lineage conversions: unnatural but useful?. Nat Biotechnol 29: 892-907.
127. Vierbuchen T, Wernig M. 2012. Molecular roadblocks for cellular reprogramming. Mol Cell 47: 827-838.
128. Visvader JE, Lindeman GJ. 2008. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
129. White RM, Zon LI. 2008. Melanocytes in development, regeneration, and cancer. Cell Stem Cell 3: 242-52.
130. Wong DJ, Segal E, Chang HY. 2008. Stemness, cancer and cancer stem cells. Cell Cycle 7: 3622-4.
131. Wu Z, Chen J, Ren J, et al. 2009. Generation of pig induced pluripotent stem cells with a druginducible system. J Mol Cell Biol 1: 46-54.
132. Yamaguchi Y, Brenner M, Hearing VJ. 2007. The regulation of skin pigmentation. J Biol Chem 282: 27557-61.
133. Yamanaka S. 2012. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10(6): 678-84.
134. Yamane T, Hayashi S, Mizoguchi M, Yamazaki H, Kunisada T. 1999. Derivation of melanocytes from embryonic stem cells in culture. Dev Dyn 216: 450-8.
135. Yang CC, Cotsarelis G. 2010. Review of hair follicle dermal cells. J Dermatol Sci 57: 2-11.
136. Yang R, Jiang M, Kumar SM, et al. 2011. Generation of melanocytes from induced pluripotent stem cells. J Invest Dermatol 131: 2458-66.
137. Youssef KK, Lapouge G, Bouvree K, et al. 2012. Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation. Nat Cell Biol 14: 1282-94.
138. Yu J, Vodyanik MA, Smuga-Otto K, et al. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-20.
139. Zabierowski SE, Herlyn M. 2008. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol 26: 2890-4.